AstraZeneca (AZN) says Imfinzi and Imfinzi plus tremelimumab delayed disease progression in Phase III POSEIDON trial for 1st-line treatment of Stage IV NSCLC

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. PRIM
3. MU
4. DPZ
5. ACN
6. NAVN
7. DFTX
8. IBM
9. META
10. ENRD

Go back to AstraZeneca (AZN) says Imfinzi and Imfinzi plus tremelimumab delayed disease progression in Phase III POSEIDON trial for 1st-line treatment of Stage IV NSCLC

AstraZeneca (AZN) Resumes Trading

October 28, 2019 12:03 PM EDT

AstraZeneca (NYSE: AZN) Resumes Trading

... More

Merck (MRK) Trades Lower Following AstraZeneca (AZN) Imfinzi Results, Down 0.70%

October 28, 2019 11:39 AM EDT

Merck (NYSE: MRK) Trades Lower Following AstraZeneca (NYSE: AZN) Imfinzi Results, Down 0.70%

... More

AstraZeneca (AZN) Halted, News Pending

October 28, 2019 11:21 AM EDT

AstraZeneca (NYSE: AZN) Halted, News Pending

... More